Literature DB >> 15655789

A combination of antigenic regions of Toxoplasma gondii microneme proteins induces protective immunity against oral infection with parasite cysts.

Elisa Beghetto1, Henrik V Nielsen, Paola Del Porto, Wilma Buffolano, Silvia Guglietta, Franco Felici, Eskild Petersen, Nicola Gargano.   

Abstract

Infection with Toxoplasma gondii causes morbidity and mortality in congenitally infected and immunocompromised individuals. Both humoral and cell-mediated immunity are involved in host resistance to invasion of the parasite. Among putative vaccine candidates, the T. gondii microneme proteins appear to be promising, because they are responsible for the invasion process. The present work focused on studying the immunogenicity of microneme proteins in infected individuals and in a mouse model of chronic toxoplasmosis. We identified 5 distinct antigenic regions within MIC2, MIC4, MIC2-associated protein, and apical membrane antigen 1 gene products, which were recognized by (1) T cells from both adults with acquired infection and children with congenital infection and (2) antibodies from all patients. Finally, we demonstrated that DNA immunization with microneme fragments elicited effective protection in mice (84% reduction in brain-cyst burden), suggesting that a combination of these antigenic regions should be considered in the design of potential vaccines against toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15655789     DOI: 10.1086/427660

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

2.  Toxoplasma gondii microneme protein 8 (MIC8) is a potential vaccine candidate against toxoplasmosis.

Authors:  M M Liu; Z G Yuan; G H Peng; D H Zhou; X H He; C Yan; C C Yin; Y He; R Q Lin; H Q Song; X Q Zhu
Journal:  Parasitol Res       Date:  2010-02-23       Impact factor: 2.289

3.  Chimeric antigens of Toxoplasma gondii: toward standardization of toxoplasmosis serodiagnosis using recombinant products.

Authors:  Elisa Beghetto; Andrea Spadoni; Luca Bruno; Wilma Buffolano; Nicola Gargano
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Evaluation of the Protective Effect of Deoxyribonucleic Acid Vaccines Encoding Granule Antigen 2 and 5 Against Acute Toxoplasmosis in BALB/c Mice.

Authors:  Xiao Teng Ching; Mun Yik Fong; Yee Ling Lau
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

5.  Toxoplasma: Immunity and Pathogenesis.

Authors:  Imtiaz A Khan; Charlotte Ouellette; Keer Chen; Magali Moretto
Journal:  Curr Clin Microbiol Rep       Date:  2019-02-04

Review 6.  The CD8 T-cell road to immunotherapy of toxoplasmosis.

Authors:  Rajarshi Bhadra; Jason P Gigley; Imtiaz A Khan
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

Review 7.  CD8+ T cell immunity in an encephalitis model of Toxoplasma gondii infection.

Authors:  SuJin Hwang; Imtiaz A Khan
Journal:  Semin Immunopathol       Date:  2015-05-06       Impact factor: 9.623

8.  Use of recombinant antigens for early postnatal diagnosis of congenital toxoplasmosis.

Authors:  Wilma Buffolano; Elisa Beghetto; Mariassunta Del Pezzo; Andrea Spadoni; Manlio Di Cristina; Eskild Petersen; Nicola Gargano
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

9.  Recombinant ROP2, ROP4, GRA4 and SAG1 antigen-cocktails as possible tools for immunoprophylaxis of toxoplasmosis: what's next?

Authors:  Bozena Dziadek; Anna Brzostek
Journal:  Bioengineered       Date:  2012-08-15       Impact factor: 3.269

10.  Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain.

Authors:  Jason P Gigley; Barbara A Fox; David J Bzik
Journal:  Infect Immun       Date:  2009-09-21       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.